Sentences with phrase «for precision cancer medicine»

Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.

While determining the genetic makeup of a patient's tumor is a critical tool for precision cancer medicine, the report's authors noted several challenges and unanswered questions about large - scale clinical application of the methods.

Not exact matches

Syapse is on a mission to deliver the best care for every cancer patient through precision medicine.

«Without Cancer Research UK and their vision for cancer precision medicine, and the commitment of the other stakeholders, we couldn't get PRECISION Panc up and running.&Cancer Research UK and their vision for cancer precision medicine, and the commitment of the other stakeholders, we couldn't get PRECISION Panc up and running.&cancer precision medicine, and the commitment of the other stakeholders, we couldn't get PRECISION Panc up and runninprecision medicine, and the commitment of the other stakeholders, we couldn't get PRECISION Panc up and runninPRECISION Panc up and running.»

«New era in precision medicine for pancreatic cancer.»

Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said, «Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaCancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said, «Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaCancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said, «Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olacancer cells to become resistant to the precision medicine olaparib.

Study co-leader Wyndham Wilson, M.D., Ph.D., NCI Center for Cancer Research, added, «This is the first clinical study to demonstrate the importance of precision medicine in lymphomas.»

«New three - in - one blood test opens door to precision medicine for prostate cancer: Test picks out men for treatment, detects early signs of resistance and monitors cancer's evolution over time.»

In the era of precision medicine, targeting the mutations driving cancer growth, rather than the tumor site itself, continues to be a successful approach for some patients.

«Researchers ID cancer gene - drug combinations ripe for precision medicine: Yeast, human cells and bioinformatics help develop one - two punch approach to personalized cancer therapy.»

This discovery could potentially be another avenue for precision medicine, which would allow cancer treatment to be tailored to the patient's DNA.

The new findings could be used to inform precision - medicine approaches that help minimize a person's risk for common diseases — such as diabetes, cardiovascular disease and cancer — by tailoring diet - based prevention and therapy to the specific needs of an individual.

In an era of precision medicine, the guideline provides recommendations for pathologists, oncologists, and other cancer health professionals on the current state - of - the - art recommendations for the molecular testing of lung cancer.

The findings are being presented as part of a poster presentation by members of the Rutgers Cancer Institute precision medicine team at the Annual Meeting of the American Association for Cancer Research (AACR) which begins this weekend in New Orleans.

This new knowledge is also making precision medicine a reality by enabling the development of highly targeted therapies that offer the potential for improved treatment outcomes, especially for patients battling cancer.

Other biomarkers and genetic signatures are being used in an effort to predict the aggressiveness of an individual patient's prostate cancer, «but the current information doesn't make it possible for their gene signature to be an actual target for precision medicine targeted therapy,» Ellis explained.

MacConaill noted that the results of Profile genomic testing are being used to further research within the institutions and are being shared more widely with initiatives like Project GENIE of the American Association for Cancer Research (AACR), which will help advance the field of precision medicine.

This new commitment to the precision medicine initiative will provide additional opportunities over the next three years for physicians to analyze the genomic profiles of pediatric patients to better understand their cancers and help improve treatment options.

«In identifying a specific abnormality in a patient's cancer instead of the overall organ where it first presented, the opportunity exists to provide tailored therapies for patients,» notes Lorna Rodriguez, MD, PhD, director of the precision medicine initiative at the Cancer Institute and professor of obstetrics, gynecology and reproductive sciences at Robert Wood Johnson Medical Scancer instead of the overall organ where it first presented, the opportunity exists to provide tailored therapies for patients,» notes Lorna Rodriguez, MD, PhD, director of the precision medicine initiative at the Cancer Institute and professor of obstetrics, gynecology and reproductive sciences at Robert Wood Johnson Medical SCancer Institute and professor of obstetrics, gynecology and reproductive sciences at Robert Wood Johnson Medical School.

Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $ 300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.

The Oncology Research Information Exchange Network, or ORIEN, is the world's largest precision collaboration for cancer research, one that will enable researchers and clinicians to share data to accelerate the development of precision medicine treatments.

I use precision medicine to create better treatment options for all women who have ovarian cancer.

Dr. Andrew Hsieh of the Human Biology Division is teaming up with colleagues at Fred Hutch and Memorial Sloan Kettering Cancer Center to make progress toward precision medicine for patients with prostate cCancer Center to make progress toward precision medicine for patients with prostate cancercancer.

On Dec. 1 - 2, those issues will come to the fore as national experts in genetics, medicine, law, big data and other fields gather for Frontiers in Precision Medicine II: Cancer, Big Data and the Public, a unique precision medicine symposium at the University of Utah S.J. Quinney College of Law, Center for Law and Biomedical Sciences, University of Utah Health Sciences, Huntsman Cancer Institute, and University of Utah Center for Excellence in ELSI Research (UCEER) addresses those topics as precision medicine is gaining more attention nationwide from health care systems, practitioners, researchers, insurers and federal amedicine, law, big data and other fields gather for Frontiers in Precision Medicine II: Cancer, Big Data and the Public, a unique precision medicine symposium at the University of Utah S.J. Quinney College of Law, Center for Law and Biomedical Sciences, University of Utah Health Sciences, Huntsman Cancer Institute, and University of Utah Center for Excellence in ELSI Research (UCEER) addresses those topics as precision medicine is gaining more attention nationwide from health care systems, practitioners, researchers, insurers and federal aMedicine II: Cancer, Big Data and the Public, a unique precision medicine symposium at the University of Utah S.J. Quinney College of Law, Center for Law and Biomedical Sciences, University of Utah Health Sciences, Huntsman Cancer Institute, and University of Utah Center for Excellence in ELSI Research (UCEER) addresses those topics as precision medicine is gaining more attention nationwide from health care systems, practitioners, researchers, insurers and federal amedicine symposium at the University of Utah S.J. Quinney College of Law, Center for Law and Biomedical Sciences, University of Utah Health Sciences, Huntsman Cancer Institute, and University of Utah Center for Excellence in ELSI Research (UCEER) addresses those topics as precision medicine is gaining more attention nationwide from health care systems, practitioners, researchers, insurers and federal amedicine is gaining more attention nationwide from health care systems, practitioners, researchers, insurers and federal agencies.

What was once dismissed as futuristic has now become reality for some cancer patients, and with leading - edge research and groundbreaking partnerships, City of Hope stands in the precision medicine vanguard.

Two new precision medicine tests that look beyond cancer genes to identify novel therapeutic targets have just received New York State Department of Health approval and are now available to both oncologists and cancer researchers for use at the front lines of patient care.

The tests are based on research conducted by Columbia University Irving Medical Center (CUIMC) investigators — and could pave the way for a more precise approach to cancer therapy and help find effective drugs when conventional approaches to precision medicine have failed.

Current precision medicine approaches aim to disable those mutated genes, and many cancer patients today have their tumors analyzed for mutated genes that can be treated with available targeted therapies.

The difference in expression patterns of individual cancers observed in the study strongly reinforces the need for personalized cancer treatment based on precision medicine.

Atul Butte, PhD, who is Priscilla Chan and Mark Zuckerberg Distinguished Professor at UCSF and directs the Institute for Computational Health Sciences, a hub for precision medicine research on campus, echoed the excitement felt across UCSF about moving towards clinical application of precision medicine: «Precision medicine is not just a «nice idea» at UCSF — it is benefitting real people, from cancer patients with unusual tumor mutations to children with undiagnosed genetic diseases.

For example, the translational laboratory is providing support to a precision medicine - based clinical trial for patients with early - stage, triple - negative breast cancFor example, the translational laboratory is providing support to a precision medicine - based clinical trial for patients with early - stage, triple - negative breast cancfor patients with early - stage, triple - negative breast cancer.

My Cancer Genome is a precision cancer medicine knowledge resource for physicians, patients, caregivers and researCancer Genome is a precision cancer medicine knowledge resource for physicians, patients, caregivers and researcancer medicine knowledge resource for physicians, patients, caregivers and researchers.

Targeting each patient's particular form of cancer is a goal of an increasingly popular clinical model called «precision medicine,» which aims to tailor treatment for each patient.

If successful, this precision medicine approach may not only benefit metastatic melanoma patients, but could also serve as a model for other types of cancers.

The Center for Cancer Targeted Therapies (C2T2) integrates a phase I - Ib / early clinical trials program, a precision cancer medicine infrastructure with expertise on tumor tissue - based state - of - the - art molecular methods, and a core resource with novel non-invasive functional imaging meCancer Targeted Therapies (C2T2) integrates a phase I - Ib / early clinical trials program, a precision cancer medicine infrastructure with expertise on tumor tissue - based state - of - the - art molecular methods, and a core resource with novel non-invasive functional imaging mecancer medicine infrastructure with expertise on tumor tissue - based state - of - the - art molecular methods, and a core resource with novel non-invasive functional imaging methods.

The bioconjugate has applications in combination and theranostic treatments for cancer, and in precision medicine to diversify targeting based on patient - specific panomics analyses.

National Cancer Institute and ECOG - ACRIN announce the July 2015 opening of the NCI - MATCH / EAY131 trial, a multi-arm phase II precision medicine study that seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of cancerCancer Institute and ECOG - ACRIN announce the July 2015 opening of the NCI - MATCH / EAY131 trial, a multi-arm phase II precision medicine study that seeks to determine whether targeted therapies for people whose tumors have specific gene mutations will be effective regardless of cancercancer type.

«This is the first precision medicine clinical trial for dogs with lung cancer,» says Dr. Wendy Lorch, DVM, PhD, principal investigator of the trial.

About Blog Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine.